AUROPHARMA.NSAUROPHARMA.NSNSE
Loading
EBITDA Margin Over TimeStable
Percentile Rank36
3Y CAGR+3.3%
5Y CAGR-0.5%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
+3.3%/yr
vs -5.6%/yr prior
5Y CAGR
-0.5%/yr
Recent acceleration
Acceleration
+9.0pp
Accelerating
Percentile
P36
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
2 yr
Consecutive growthStable
PeriodValueYoY Change
202520.29%+2.1%
202419.87%+35.9%
202314.62%-20.5%
202218.38%-15.6%
202121.78%+4.7%
202020.79%+2.2%
201920.34%-12.3%
201823.19%-0.4%
201723.27%-0.0%
201623.28%-